Neurocrine Biosciences, Inc. (NBIX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Neurocrine Biosciences, Inc. (NBIX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Fiscal Year: January - December
Neurocrine Biosciences, Inc. (NBIX), listed on the NASDAQ, has a market capitalization of $. As of Dec 07, 2025, the stock is trading at $155.51 per share, offering investors a clear view of its current market value. Neurocrine Biosciences, Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 37.1, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Neurocrine Biosciences, Inc. also offers a dividend yield of N/A , making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Neurocrine Biosciences, Inc. (NBIX) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Neurocrine Biosciences, Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Neurocrine Biosciences, Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Neurocrine Biosciences, Inc. is 26.14, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Neurocrine Biosciences, Inc. (NBIX) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Neurocrine Biosciences, Inc. (NBIX) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Neurocrine Biosciences, Inc. (NBIX) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Neurocrine Biosciences, Inc.. To access the full SS Score, consider upgrading your subscription.
Neurocrine Biosciences, Inc. is a significant player in the industry sector, with a market capitalization of $ and a competitive P/E ratio of 37.1. Investors should compare these metrics with industry peers to gauge whether Neurocrine Biosciences, Inc. is outperforming or underperforming within its sector.
Neurocrine Biosciences, Inc. (NBIX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Published, peer-reviewed narrative review in CNS Spectrums compiles pharmacologic, pharmacokinetic and clinical data of VMAT2 inhibitors to highlight important differences between treatments Review pr...
Nvidia earnings have cast a light on defensive areas, inducing a sector rotation that may accelerate in the short term. Looking beyond NVDA earnings, an economic environment characterized by slowing g...
Neurocrine Biosciences looks meaningfully undervalued, with ongoing growth from Ingrezza, a strong launch for Crenessity, and a promising pipeline. NBIX is looking to grow Ingrezza's market share with...
Neurocrine Biosciences, Inc. ( NBIX) Jefferies London Healthcare Conference 2025 November 18, 2025 7:00 AM EST Company Participants Kyle Gano - CEO & Director Eric Benevich - Chief Commercial Officer...
SAN DIEGO , Nov. 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences: Jeffer...
On Monday, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) said its Phase 2 study of NBI-1070770 in adults with major depressive disorder did not meet the primary endpoint compared to placebo, though it wa...
SAN DIEGO , Nov. 10, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 2 study evaluating the efficacy, safety and tolerability of investigational compoun...
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2025 Earnings Call October 28, 2025 4:30 PM EDT Company Participants Todd Tushla Kyle Gano - CEO & Director Matthew Abernethy - Chief Financial Officer E...
Achieved Total Net Product Sales of $790 Million Representing 28% Year-Over-Year Growth INGREZZA® (valbenazine) Third-Quarter 2025 Net Product Sales of $687 Million Representing 12% Year-Over-Year Gro...
Neurocrine Biosciences is rated BUY, driven by strong INGREZZA sales, Prenepsi growth, and a promising late-stage neuropsychiatry pipeline. NBIX's Q2 2025 revenue reached $682 million, with INGREZZA c...
Continuous treatment with INGREZZA 40 mg for 48 weeks resulted in sustained, clinically meaningful improvements in tardive dyskinesia symptoms 90% of participants who completed 48 weeks of continuous ...
Conference Call and Webcast Scheduled for Tuesday, October 28 SAN DIEGO , Oct. 7, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quart...
SAN DIEGO , Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Mike Sibley as Senior Vice President and General Manager of the company's Neurop...
Once-daily INGREZZA treatment was generally well tolerated and showed early and sustained improvements in chorea severity Findings presented at 2025 MDS International Congress of Parkinson's Disease a...
The KINECT-PRO™ analysis is the first and only of its kind to report both remission of tardive dyskinesia symptoms and associated improvements in patient-reported outcomes. Post-hoc analysis from KINE...
SAN DIEGO , Sept. 22, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new data from the Phase 2 SAVITRI™ study, which showed statistically signific...
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit September 17, 2025 12:40 PM EDT Company Participants Kyle Gano - CEO & Director ...
Additional Data from SAVITRI™ Study Expand on Top-Line Results Announced in April 2024 SAVITRI Poster Presentation Chosen as Finalist for Psych Congress Poster Awards SAN DIEGO , Sept. 16, 2025 /PRNew...
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:45 AM EDT Company Participants Kyle Gano - CEO & Director Sanjay Keswani - Chie...
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Cantor Global Healthcare Conference 2025 September 3, 2025 1:00 PM EDT Company Participants Matthew Abernethy - Chief Financial Officer Eric Benevich - Chie...
SAN DIEGO , Aug. 26, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at four investor conferences in September. Chief Financial Officer Matt Abernethy, Chief Commerci...
SAN DIEGO , Aug. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Canaccord Genuity 45th Annual Growth Conference at 8:00 a.m. ET on Wednesday, August 13, 20...
Neurocrine (NBIX) Q2 Revenue Jumps 17%
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2025 | 701.16M | 25.84% | Est @25.8% |
| 2026 | 845.12M | 20.53% | Analyst x5 |
| 2027 | 1,209.84M | 43.16% | Analyst x5 |
| 2028 | 1,283.48M | 6.09% | Analyst x4 |
| 2029 | 1,209.50M | -5.76% | Analyst x4 |
| 2030 | 1,183.65M | -2.14% | Est @-2.1% |
| 2031 | 1,174.68M | -0.76% | Est @-0.8% |
| 2032 | 1,177.06M | 0.20% | Est @0.2% |
| 2033 | 1,187.39M | 0.88% | Est @0.9% |
| 2034 | 1,202.27M | 1.25% | Est @1.3% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2023A | 361.60M | 1.00 | 361.60M |
| 2024A | 557.20M | 1.00 | 557.20M |
| 2025E | 701.16M | 1.08 | 650.23M |
| 2026E | 845.12M | 1.16 | 726.79M |
| 2027E | 1.21B | 1.25 | 964.87M |
| 2028E | 1.28B | 1.35 | 949.24M |
| 2029E | 1.21B | 1.46 | 829.54M |
| 2030E | 1.18B | 1.57 | 752.84M |
| 2031E | 1.17B | 1.70 | 692.86M |
| 2032E | 1.18B | 1.83 | 643.83M |
| 2033E | 1.19B | 1.97 | 602.30M |
| 2034E | 1.20B | 2.13 | 565.55M |
| Terminal | 23.11B | 2.13 | 10.87B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.